Lei Jianping on January 9
iFLYTEK (**002230) announced today that the company intends to spin off its holding subsidiary, iFLYTEK Medical, to be listed on the main board of the Hong Kong Stock Exchange.
The issuance size of iFLYTEK Medical does not exceed 15% of the total share capital after the issuance, and the issuance method is a Hong Kong public offering and an international placement of new shares.
iFLYTEK is a comprehensive artificial intelligence company, whose main business includes core AI application scenarios and industrial chain links such as smart education, open platform and consumer business, smart city, operator, smart car, smart finance, and smart healthcare.
iFLYTEK said that the proposed spin-off assets iFLYTEK Medical will carry out R&D and services in the medical field, and rely on its own artificial intelligence technology related to the medical industry to carry out project development, system operation and maintenance, product sales and other main business activities in the fields of auxiliary diagnosis and treatment, medical insurance management, and intelligent hardware.
After the completion of this spin-off, iFLYTEK Medical will deeply cultivate the medical industry market, and iFLYTEK will focus on improving the performance level of the product layout of artificial intelligence core technologies and general large models and other major application scenarios.
Annual revenue of 49.4 billion net loss of 2600 million
According to reports, iFLYTEK Medical is an enterprise that uses AI to empower China's medical industry, with the mission of creating "AI diagnosis and treatment assistants for every doctor and AI health assistants for everyone".
Through leading core technologies such as speech recognition, image recognition, and natural language understanding, iFLYTEK is committed to deeply integrating artificial intelligence technology with the medical industry, promoting the development of the health care industry, and helping the implementation of national medical reform policies.
iFLYTEK has achieved good results in improving the informatization and intelligence level of hospitals, improving the diagnosis and treatment capabilities of grassroots doctors, and empowering medical institutions at all levels, regional management platforms, residents and patients.
According to the announcement, iFLYTEK Medical's revenue in 2020, 2021, and 2022 will be 3200 million yuan, 35.6 billion yuan, 49.4 billion yuan;The net loss was 19.23 million yuan and 10.3 billion yuan, 2600 million yuan;The net profit after deducting non-profits was 14.28 million yuan, -83.56 million yuan and -2$1.6 billion.
iFLYTEK directly holds 5247%
iFLYTEK Medical's equity also followed**. According to the announcement, iFLYTEK shares hold 52 shares of iFLYTEK Medical47% of the shares, Hefei Zhengsheng Information Technology Partnership (Limited Partnership) holds 1711%, Anhui Kexun Venture Capital ** Partnership (Limited Partnership) holds 1503%, Hu Guoping holds 394%, Shenzhen Tianzheng Investment *** holds 343%, Zibo Jizhi Equity Investment ** Partnership (Limited Partnership) holds 153%；
Shanghai Shuiyao Enterprise Management Consulting Services Co., Ltd. holds 132%, Anhui Yanzhi Technology *** holds 119%, iFLYTEK Haihe (Tianjin) Artificial Intelligence Venture Capital ** Partnership (Limited Partnership) holds 113%；
Hainan Yuntong Equity Investment Partnership (Limited Partnership) holds 092%, Hefei Tongchuang SME Development ** Partnership (Limited Partnership) holds 066%；
Shenzhen Guoke Ruihua Phase III Equity Investment** Partnership holds 066%, Shanghai Guyu Nange Science and Technology Development Center Limited Partnership) holds 036%, Hefei Kexun Lianshan Innovation Industry Investment ** Partnership (Limited Partnership) holds 026%。
iFLYTEK is the controlling shareholder of iFLYTEK Medical, and Liu Qingfeng and HKUST Holdings are the actual controllers of iFLYTEK Medical.
Lei Di was founded by ** Lei Jianping, if ** please in**.